Browsing by Author "Vulsteke, C."
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item ENGOT-EN9/LEAP-001: A PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB PLUS LENVATINIB COMPARED WITH CHEMOTHERAPY IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER(2020) Randall, L.; Marth, C.; Vulsteke, C.; Rubio, M. Jesus; Makker, V.; Braicu, I.; McNeish, I.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S.; Lee, J.; Pignata, S.Item ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer(2020) Marth, C.; Vulsteke, C.; Rubio, M. J. R.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S.; Lee, J.; Pignata, S.; AAJ-5802-2021Item ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer(2019) Marth, C.; Vulsteke, C.; Rubio, M. J.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Radoslaw, M.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S. M.; Lee, J.; Pıgnata, S.